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httpicense.Abstract Increased application of DNA ﬁngerprinting has advanced the understanding of the
dynamics of TB epidemiology. Typing of MTB is important for case tracing, and identifying com-
munity outbreaks.
Objective: We aim to detect pattern of drug resistance and molecular genotypes of MTB at
Mansoura hospitals using PCR-RFLP.
Methodology: 123 sputum samples obtained from ZN smear positive cases were cultivated on
Lowenstein Jensen (LJ) medium, out of them 67 specimens (54.5%) were positive culture. Genotypic
analysis was done by the RFLP method after DNA extraction and PCR ampliﬁcation. The suscepti-
bilities to isoniazid (INH), rifampicin (RIF), streptomycin (STR) and ethambutol (EMB) were deter-
mined by the indirect nitrate reductase assay.
Results: The identiﬁed restriction patterns yielded 3 bands with different sizes and revealed 3 geno-
types only. Restriction patterns are equal to 245/125/100 bp, and 245/125/80 bp fragments for Bst EII
digests and 155/140/60 bp (MTC), 155/110/70 bp (intracellulare) and 160/140/70 bp (malmoense)
fragments for Hae III digest. Genotyping of MTB detected that MTC was the commonest genotypefathy_amal@hotmail.com (A.
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370 A.M. Abd-El Aal et al.among studied cases 49/67 (73.1%), followed by Mycobacterium intracellulare 14/67 (20.9%), while
Mycobacterium malmoense had the least incidence 4/67. There was signiﬁcant increased risk of resis-
tance to STM, RIF, ETH and INH with M. intracellulare (p= 0.021, p< 0.001, p= 0.001,
p< 0.001) while MTC showed lower resistance to STM, RIF, ETH and INH and allM. malmoense
isolates showed no resistance.
Conclusion: PCR-RFLP was found to be a simple and reproducible method for genotyping of
MTB strains and for early detection ofMycobacterium tuberculosis infection.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.Introduction
Tuberculosis is more prevalent in developing countries, in
which up to 95% of cases occur [1]. It remains a major chal-
lenge to global public health in the 21st century, especially
with the steady increase in drug resistant TB [2]. The key
of controlling the spread of tuberculosis includes proper case
ﬁnding, rapid diagnosis, immediate initiation of effective
therapy and contact tracing to arrest further transmission
[3]. Recent developments in DNA technology and molecular
biology methods have led to rapid detection of mycobacterial
DNA by nucleic acid ampliﬁcation [4]. Genotyping methods
of TB include DNA ﬁngerprinting, RFLP based on the poly-
morphism of the insertion sequence IS6110 among MTB
complex strains, ﬁngerprinting based on the polymorphic
GC rich sequence (PGRS), Spoligotyping and variable-num-
ber tandem repeats (VNTR) typing based on the analysis of
polymorphisms in the DR locus. Among these methods, the
IS6110 ﬁngerprinting is the recommended standard primary
genotyping method and has been used routinely worldwide
[5].
The increased application of DNA ﬁngerprinting has ad-
vanced the understanding of the dynamics of TB epidemiol-
ogy. The typing of Mycobacterium tuberculosis strain is
important for case tracing, distinguishing between relapse
and reinfection by an exogenous strain and identifying noso-
comial, institutional and community outbreaks. Also it can
be applied to conﬁrm recent transmission of tuberculosis in
a linked population or lab cross contamination [6]. Clinical
isolates of MTB obtained from patients infected by the same
strain of bacillus usually exhibit identical or very similar ﬁn-
gerprint patterns, and the patients are more often found to
be epidemiologically linked [5]. Restriction fragment length
polymorphism (RFLP) techniques have been developed for
several mycobacterial genes but the one most investigated
and validated is heat shock protein (hsp65). The restriction
patterns are highly distinct by this method and can be iden-
tiﬁed visually [7]. Moreover the reliability of PCR-RFLP re-
sults with one enzyme is augmented if the results are
conﬁrmed with a second restriction enzyme [8].
Restriction fragment length polymorphism (RFLP) tech-
niques have been developed for several mycobacterial genes
but the one most investigated and validated is heat shock pro-
tein (hsp65). The restriction patterns are highly distinct by this
method and can be identiﬁed visually [7]. Moreover the reli-
ability of PCR-RFLP results with one enzyme is augmented
if the results are conﬁrmed with a second restriction
enzyme [8]. The 65 kDa hsp65 is one of the major immuno-
reactive proteins of the mycobacteria. In 1993, a method fordifferentiating among slow growing mycobacterium species
by hsp65 gene based restriction fragment length polymorphism
(RFLP) analysis was developed using simple DNA extraction
followed by a PCR step based on ampliﬁcation of a 439 bp
fragment of hsp65 gene involving genus speciﬁc primers [9].Aim of work
The aim of this study is to detect pattern of drug resistance and
molecular genotypes of M. tuberculosis at Mansoura hospitals
using restriction fragment length polymorphism RFLP.Subjects and methods
This study was carried out on 123 ZN positive sputum
samples collected from pulmonary TB patients either new
patients never treated or were previously treated after per-
mission from human ethics committee at the university
and the relevant authorities during the approval of the pro-
posal. All cases were cultivated on Lowenstein Jensen (LJ)
medium, out of them 67 specimens (54.5%) were culture
positive. They were 51 males and 16 females and their
age ranged from 15–70 years. Patients were selected from
Mansoura University Hospitals and Mansoura Chest
Hospital.
The patients were subjected to – full history taking espe-
cially for past history of similar conditions and intake of
anti-TB drugs From all patients, sputum samples were col-
lected and subjected to the following microbiological
examinations:
1. Mycobacterial cultures on Lowenstein-Jensen (LJ) media.
2. Antimycobacterial susceptibility tests (AST) were done by
indirect nitrate reductase assay (indirect NRA) for strepto-
mycin (STM), isoniazid (INH), rifampicin (RIF) and eth-
ambutol (ETH).
Genotypic analysis
It included three main steps:
1- DNA extraction to release DNA from mycobacterial
cells.
2- Ampliﬁcation of the target part of gene by PCR and
detection by agarose gel electrophoresis.
3- RFLP analysis of the ampliﬁed DNA.
Drug resistance patterns of Mycobacterium tuberculosis 3711-DNA extraction [10]
d. DNA extraction
Chromosomal DNA was extracted from growth harvested
from surface of Lowenstein Jensen (LJ) medium by the simple
boiling method. In short, few colonies were removed and sus-
pended in 500 ll of sterile double distilled water and was
boiled for 10 min. After centrifugation at 12000g for 3 min,
5 ll of supernatant was used for the PCR.
2-DNA ampliﬁcation [11]
439 bp fragment of hsp65 gene was ampliﬁed by using Tb11
genus speciﬁc primers and restriction enzyme analysis for
digestion of products with HaeIII & BstEII enzymes was
employed.
Primer sequence
Forward primer: Hsp (50 ACC AAC GAT GGT GTG TCC
AT 30).




(1) External DNA markers (50 bp).
(2) Restriction enzymes (HaeIII, BstEII) and digestion buf-
fer (Biolabs, New England).
(3) Ampliﬁed PCR product.Restriction enzyme analysis:
Bst EII and Hae III restriction enzymes
(4) The interpretation of results was done according to the
following diagram
Results
Demographic data, smoking, and history of treatment of the
67 culture positive pulmonary TB patients were 51 (67.1%)
males and 16 (23.9%) females, represent 27 (40.3%) new cases,
and 40 (59.7%) previously treated cases, with age ranged from
15 to 70 years (mean age was 41.1 years). Cough was the com-
monest clinical presentation in 50/67 (74.6%) followed by fe-
ver in 39/67 (58.2%), then weight loss in 36/67 (53.7%), and
chest pain in 27/67 (40.3%). Hemoptysis was the least present-
ing feature in the studied patients in 19/67 (28.4%). Mean
tuberculin test diameter was 18.6 mm in all cases while Mean
ESR was 39.1 mm at ﬁrst hour and 70.94 mm at second hour
(data not shown). Table 1 shows MTB genotypes and restric-Table 1 Genotyping and restriction bands of the isolated MTB.
Genotypes Restriction Enzyme
Mycobacterial tuberculosis complex (MTC) BST EIIﬁ 245/125
M. intracellulare BST EIIﬁ 245/125
M. malmoense BST EIIﬁ 245/125tion of ampliﬁed DNA product that were done by BST E II
enzyme which yielded 2 patterns of bands 245/125/80 bp and
245/125/100 bp and Digestion by Hae III enzyme gave 3 pat-
terns of restriction bands 160/140/70 bp, 155/110/60 bp and
155/140/70 bp. For more clariﬁcation:
1. BST EII enzyme yield 245/125/80 bp and Hae III enzyme
yield 160/140/70 bp that reﬂect (M. tuberculosis complex)
(MTC) in 73.1% (49/67) of studied cases
2. BST EII enzyme yield 245 /125/100 bp & Hae III enzyme
yield 155/140/60 bp pattern that reﬂect (Mycobacterium
intracellulare) in 14/67 (20.9%) of cases while
3. BST EII enzyme yield 245/125/100 bp & Hae III enzyme
yield 155/110/70 bp pattern that reﬂect (Mycobacterium
malmoense) in 4/67 (6.0%) of cases.
Moreover, there were no signiﬁcant differences between
each of Mtb genotypes (MTC, M. intracellulare and M.
malmoense) and sex, residence, smoking habit, or clinical pre-
sentation in the tuberculous patients (data not shown). Table 2
shows isolated genotypes in new cases and previously treated
tuberculous cases. There was an insigniﬁcant association be-
tween history of treatment and isolated genotypes. Table 3
shows drug susceptibility patterns according to previous treat-
ment in tuberculous patients. Risk of resistance to 4 drugs and
3 drugs was insigniﬁcantly higher in previously treated than
new cases (p= 0.084, 0.217). Table 4 shows separate drug sus-
ceptibility patterns of ﬁrst line anti-TB drugs in relation to his-
tory of treatment. Previously treated cases had signiﬁcantly
higher resistance to INH versus new cases (p= 0.040), how-
ever there is no signiﬁcant difference to STM, RIF or ETH
resistance between both groups. Table 5 shows drug suscepti-
bility patterns in relation to isolated genotypes. There were sig-
niﬁcant relations between various genotypes and drug
susceptibility patterns (p= 0.014); M. All cases of M. malmo-
ense were sensitive to 4 drugs (100%) of cases, while all 4 drug
resistance cases were ofM. intracellulare genotype (p< 0.001),
Table 6 shows separate drug susceptibility patterns in relation to
isolated MTB genotypes. There was signiﬁcant increased risk of
resistance to STM, RIF, ETH and INH with M. intracellulare
genotype (p= 0.021, p< 0.001, p= 0.001, p< 0.001). MTC
showed lower resistance to STM, RIF, ETH and INH while all
M. malmoense isolates were sensitive to all the 1st line anti-TB
drugs.
Discussion
Tuberculosis as one of the oldest recorded human infections, is
one of the biggest killers among the infectious diseases, despite
the use of a live attenuated vaccine and antibiotics [13]. The
development of drug resistance in the population has increased
concern that TB again became an incurable disease [14].s and Bands Total (n= 67)
No %
/80 bp Hae IIIﬁ 160/140/70 bp 49 73.1
/100 bp Hae IIIﬁ 155/140/60 bp 14 20.9
/100 bp Hae IIIﬁ 155/110/70 bp 4 6.0
Table 2 Isolated genotypes in relation to new cases and previously treated tuberculous patients.
MTC M. intracellulare M. malmoense p
New cases (n= 27) 23 (85.2%) 3 (11.1%) 1 (3.7%) 0.111
Previously treated cases (n= 40) 26 (65.0%) 11 (27.5%) 3 (7.5%)
Table 3 Anti-TB susceptibility patterns of ﬁrst line treatment by indirect nitrate reductase assay in new versus previously treated
cases.
Drug resistance proﬁle Previously treated cases (40) New cases (27) p
No. % No. %
Sensitive to 4 drugs (n= 32) 16 50.0 16 50.0 0.122
Resistance to any drug (n= 35) Total (n= 35) 24 68.6 11 31.4
One drug resistance (n= 10) 6 60.0 4 40.0 0.582
Two drug resistance (n= 6) 3 50.0 3 50.0 0.769
Three drug resistance (n= 11) 8 72.7 3 27.3 0.217
Four drug Resistance (n= 8) 7 78.5 1 12.5 0.084
Table 4 Separate drug susceptibility patterns of ﬁrst line anti-TB drug in relation to history of treatment.
Previously treated cases (n= 40) New cases (n= 27) p
Sensitive Resistant Sensitive Resistant
Total cases 16 40.0 24 60.0 16 59.3 11 40.7 0.122
Streptomycin (STM) 24 60.0 16 40.0 19 70.4 8 29.6 0.385
Rifampicin (RIF) 23 57.5 17 42.5 21 77.8 6 22.2 0.086
Ethambutol (ETH) 26 65.0 14 35.0 23 85.2 4 14.8 0.068
Isoniazid (INH) 23 57.5 17 42.5 22 81.5 5 18.5 0.040
Table 5 Drug susceptibility patterns in relation to isolated genotypes.
Drug susceptibility patterns MTC M. intracellulare M. malmoense p
Sensitivity to 4 drugs (n= 32) 25 (78.1%) 2 (6.3%) 4 (12.5%) 0.014
Resistance to drugs (n= 35) Total (n= 35) 24 (68.6%) 11 (31.4%) 0 (0%)
One drug resistance (n= 10) 10 (100.0%) 0 (0%) 0 (0%) 0.322
Two drug resistance (n= 6) 5 (83.3%) 1 (16.7%) 0 (0%) 0.490
Three drug resistance (n= 11) 9 (81.8%) 2 (18.2%) 0 (0%) 0.273
Four drug resistance (n= 8) 0 (0%) 8 (100.0%) 0 (0%) <0.001
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the same strain of bacillus usually exhibit identical or very sim-
ilar ﬁngerprint patterns, and the patients are more often found
to be epidemiologically linked [5].
The aim of this study is to detect molecular genotypes and
drug resistance patterns ofM. tuberculosis at Mansoura hospi-
tals. To achieve this aim 123 sputum samples obtained from
ZN smear positive cases were cultivated on Lowenstein Jensen
(LJ) medium, out of them 67 specimens (54.5%) were positive
culture that were divided into two groups; 27/67 (40.3%) newly
diagnosed cases & 40/67 (59.7%) previously treated cases.
This study revealed that M. tuberculosis complex (MTC)
had the commonest incidence in 49/67 (73.1%), followed by
M. intracellulare in 14/67 (20.9%) while M. malmoense had
the least incidence in 4/67 (6.0%). Compared with others stud-
ies who found that 97.5% of isolates wereM. tuberculosis com-
plex (MTBC) and 2.6% were Mycobacteria other thantuberculosis (MOTT), While 22 isolates were Mycobacterium
africanum [15].
Increased prevalence of MTC genotype could be explained
as this strain is highly virulent causing extensive transmission
among patients. Moreover, geographic proximity of patients
to one another might have increased opportunities for TB
exposure and supported transmission through casual contact
[16]. As the incidence of NTM infections has increased over
the past couple of decades, the most common clinical manifes-
tation is pulmonary disease. M. malmoense and M. intracellu-
lare are two of the most important members of non
tuberculous mycobacteria [17]. Mycobacterium avium complex
(MAC) consists of several closely related slow-growing non-
chromogen mycobacteria, includingM intracellulare. MAC ac-
counts for the largest portion of all NTM infections in most
epidemiologic series. They are saprotrophic organisms that en-
ter into hosts via the gastrointestinal tract usually, but also can
Table 6 Separate drug susceptibility patterns in relation to isolated Mtb genotypes.
Drug susceptibility MTC M. intracellulare M. malmoense p value
No % No % No %
STM Sensitive (n= 43) 34 79.1 5 11.6 4 9.3 0.021
Resistant (n= 24) 15 62.5 9 37.5 0 0
RIF Sensitive (n= 44) 37 84.1 3 6.8 4 10.8 <0.001
Resistant (n= 23) 12 52.2 11 47.8 0 0
ETH Sensitive (n= 49) 40 81.6 5 10.2 4 10.0 0.001
Resistant (n= 18) 9 50.0 9 50.0 0 0
INH Sensitive (n= 45) 38 84.4 3 6.7 4 8.9 <0.001
Resistant (n= 22) 11 50.0 11 50.0 0 0
Drug resistance patterns of Mycobacterium tuberculosis 373be via the lungs [17]. M intracellulare can colonize the respira-
tory tract of patients and it may cause disease indistinguishable
from tuberculosis. M. malmoense is one of the slow growing
mycobacteria belonging to the Runyon group III. M. malmo-
ense is also reported to be the second most common non tuber-
culous mycobacterium recovered from sputum [18].In this
study restriction of ampliﬁed DNA product was done by
BST EII and Hae III restriction enzymes that yielded;
BST EIIﬁ 245/125/80 bp and Hae IIIﬁ 160/140/70 bp
(M. tuberculosis complex).
BST EIIﬁ 245/125/100 bp and Hae IIIﬁ 155/140/60 bp
(M. intracellulare).
BST EIIﬁ 245/125/100 bp and Hae IIIﬁ 155/110/70 bp
(M. malmoense).
Azar and Abdulrazagh [16] study was done on 145 clinical
isolates (96.6%) which showed identical restriction patterns
equal to 160/145/72 bp fragments for Hae III and 250/120/
82 bp fragments for Bst EII digests but diverse restriction pat-
terns were observed for ﬁve clinical isolates in Hae III digest
only, while their Bst EII digestion patterns showed no varia-
tion and were similar to other isolates. Two strains showed dif-
ferent Hae III patterns as 180/100/80 bp and 194/72 bp. The
third different Hae III digest pattern was seen in three strains
as 160/145 bp.
In our study the isolates had less than ﬁve copies. This pat-
tern is similar to that of other countries in the Asian and Ocean
regions, such as Malaysia, Oman, Hong Kong, and Madagas-
car [16,17]. While in Das et al. [18] study from south India, a
large number of isolates ofM. tuberculosis with low copy num-
bers or no copies of IS 6110 element have been observed. In
Magana-Arachchi et al. [19] RFLP analysis of the 131 isolates,
the copy number of IS 6110 element in M. tuberculosis strains
varied from 1 to 7, the majority having 3 to 5 copies which
agrees with our study.
In this study as well as in Ida et al. [20] study there was no
statistically signiﬁcant association between any clinical, epide-
miological parameter and strain clustering.
In this study also, as the susceptibilities to isoniazid (INH),
rifampicin (RIF), streptomycin (STR) and ethambutol (EMB)
were determined by the indirect nitrate reductase assay we
found that 47.8% of cases were sensitive to the four anti-tuber-
culous drugs. All patients received streptomycin, rifampicin,
ethambutol and isoniazid. ETH showed higher sensitivity
73.1% followed by INH 67.2%, RIF 65.7% then STM 64.2%.
These results were in concordance with those reported by
Abbadi et al. [5] who found that 56.8% of cases were suscep-tible to the four anti-tuberculosis drugs. Similarly Abdelaal
et al. [21] in the same locality reported that the sensitivity of
Mtb was highest for STR (64%) and EMB (56%) and lowest
for RIf (54%) and INH (48%) while Mashaly, (2011) [22]
found that the sensitivity of Mtb was higher for STM and
ETH (74.4% for each) followed by RIF (55.8%) and INH
(34.9%). On the other hand the order of the observed suscep-
tibility pattern of Mtb was different from reported in the same
locality by Zaghloul [23]. He found that the highest sensitivity
was to RIF (79%) and STM (71%) followed by INH (64%)
and the lowest sensitivity was encountered with ETH (14%).
The signiﬁcant decrease in the sensitivity ofMtb to INH and
RIF in the last 10 years could be attributed to poor compliance
and wide use of these drugs for non speciﬁc infections as well as
for certain infectious diseases like brucellosis. While the signif-
icant increase in sensitivity ofMtb to ETHwas attributed to the
restriction of its use in the management of TB patients [16].
In our study of Anti-TB susceptibility patterns of ﬁrst line
treatment by indirect nitrate reductase assay we found that
47.8% of cases were sensitive to the four anti-tuberculous
drugs while 52.2% cases were resistant to one or more drugs.
Resistance varied according to number of drugs; 11 cases
(16.4%) showed 3 drug resistance followed by 10 cases
(14.9%) showed one drug resistance, 8 (11.9%) cases showed
4 drug resistance then 6 cases (9%) showed 2 drug resistance.
Badran [24] found that among total 153 TB cases, 50 cases
(32.7%) were resistant to one or more of the ﬁrst line antitu-
berculous drugs as 48% were mono drug resistance and 52%
showed multi resistance. Similarly, Mashaly [22] showed
41.9% monodrug resistance and 46.5% cases with multi drug
resistance.
This study showed that 2 ry resistance to 1st line anti TB
drugs was higher than 1 ry resistance. This agrees with Al-
Akhali et al. [25] and Surucuoglu et al. [26] in other different
localities that found a higher prevalence of resistance among
previously treated than newly diagnosed TB patients (17.4%
vs. 9.8% and 45.5% vs. 25%, respectively). Also Mashaly
[22] showed 2 ry resistance to 1st line anti TB drugs was higher
than 1 ry resistance (93.3% and 85.7%) in the same locality.
The high resistance pattern detected in this study might be ex-
plained by previous anti-TB treatment in 40/67 patients which
has been identiﬁed as an important risk factor for the acquisi-
tion of drug resistant TB [27] Resistance against 2 or 3 drugs is
difﬁcult to treat and often results in treatment failure [28].
Multi drug resistance (resistance to at least RIF and INH)
was found in 25/67 (37.3%) cases. It is comparable to those
374 A.M. Abd-El Aal et al.reported in other different studies conducted at Mansoura hos-
pitals as reported in Mashaly [22] who found 14/43 (32.6%)
MDR isolates, Badran [24] and El-Moursy et al. [29] 26%
and 46%, respectively.
Regarding drug susceptibility patterns in relation to iso-
lated genotypes, there was a signiﬁcant difference between var-
ious genotypes and drug susceptibility patterns (p= 0.014);
M. intracellulare showed higher resistance in 11/14 of cases
(78.6%) while M. malmoense showed higher sensitivity in
100% of cases to the 4 antituberculous drugs. In Grifﬁth
et al. [30] study most strains of M. malmoense are sensitive
to ethambutol, and some are sensitive to rifampicin. As for
other NTM species the clinical response to treatment does
not correlate well with standard in vitro testing for antimicro-
bial susceptibility. Although overall cure rates remain below
50%, the best responses have been observed with combinations
of isoniazid, rifampin, and ethambutol [31].
Conclusion
Our results showed that M. tuberculosis complex (MTC) geno-
type had the commonest incidence followed by M. intracel-
lulare while M. malmoense had the least incidence. Moreover
M. intracellulare showed the higher resistance whileM. malmo-
ense showed the higher sensitivity to antituberculous drugs.
We recommend PCR-RFLP as a simple and reproducible
method for genotyping of mycobacterium tuberculosis strains
and for early detection of M. tuberculosis. This method could
also differentiate MBT complex and non tuberculous myco-
bacteria directly from clinical samples, that could help clini-
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